Published in J Int AIDS Soc on May 19, 2017
Random-effects models for longitudinal data. Biometrics (1982) 54.17
High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem (2011) 10.11
New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (2003) 8.25
Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity (2012) 6.29
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med (2010) 5.36
Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS One (2007) 2.61
Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature (2015) 2.41
HIV-1 DNA predicts disease progression and post-treatment virological control. Elife (2014) 2.07
Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. J Clin Invest (2012) 2.05
Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial. Lancet Infect Dis (2014) 1.82
Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis (2005) 1.80
Definition of the viral targets of protective HIV-1-specific T cell responses. J Transl Med (2011) 1.73
Effect of therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): a multicentre randomised clinical trial. Lancet HIV (2015) 1.67
Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection. J Infect Dis (2012) 1.61
Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. Mol Ther (2013) 1.61
Emerging strategies to deplete the HIV reservoir. Curr Opin Infect Dis (2014) 1.56
Extreme genetic fragility of the HIV-1 capsid. PLoS Pathog (2013) 1.35
Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J Infect Dis (2005) 1.32
Concurrent measures of total and integrated HIV DNA monitor reservoirs and ongoing replication in eradication trials. AIDS (2012) 1.27
Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques. Eur J Immunol (2010) 1.27
Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption. Antivir Ther (2005) 1.22
HIV-1 conserved-element vaccines: relationship between sequence conservation and replicative capacity. J Virol (2013) 1.15
Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire. J Infect Dis (2013) 1.07
Reactivation of latent HIV-1 in central memory CD4⁺ T cells through TLR-1/2 stimulation. Retrovirology (2013) 1.06
Establishment and Replenishment of the Viral Reservoir in Perinatally HIV-1-infected Children Initiating Very Early Antiretroviral Therapy. Clin Infect Dis (2015) 1.06
Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy. Vaccine (2008) 1.02
Gag-positive reservoir cells are susceptible to HIV-specific cytotoxic T lymphocyte mediated clearance in vitro and can be detected in vivo [corrected]. PLoS One (2013) 1.01
A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques. J Transl Med (2015) 0.92
Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial. J Infect Dis (2011) 0.91
Identification of effective subdominant anti-HIV-1 CD8+ T cells within entire post-infection and post-vaccination immune responses. PLoS Pathog (2015) 0.91
Roles for Treg expansion and HMGB1 signaling through the TLR1-2-6 axis in determining the magnitude of the antigen-specific immune response to MVA85A. PLoS One (2013) 0.89
Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1. J Antimicrob Chemother (2015) 0.88
Effect of lithium on HIV-1 expression and proviral reservoir size in the CD4+ T cells of antiretroviral therapy suppressed patients. AIDS (2014) 0.86
Modified vaccinia virus Ankara-infected dendritic cells present CD4+ T-cell epitopes by endogenous major histocompatibility complex class II presentation pathways. J Virol (2014) 0.84
Expansion of interferon-γ-secreting HIV-specific T cells during successful antiretroviral therapy. HIV Med (2012) 0.83
Defining the HLA class I-associated viral antigen repertoire from HIV-1-infected human cells. Eur J Immunol (2015) 0.83
Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA. HIV Med (2005) 0.83
Reactivation Kinetics of HIV-1 and Susceptibility of Reactivated Latently Infected CD4+ T Cells to HIV-1-Specific CD8+ T Cells. J Virol (2015) 0.81
Developing Combined HIV Vaccine Strategies for a Functional Cure. Vaccines (Basel) (2013) 0.77
Short-term Treatment With Interferon Alfa Diminishes Expression of HIV-1 and Reduces CD4+ T-Cell Activation in Patients Coinfected With HIV and Hepatitis C Virus and Receiving Antiretroviral Therapy. J Infect Dis (2015) 0.77
Sensitive quantification of the HIV-1 reservoir in gut-associated lymphoid tissue. PLoS One (2017) 0.75